/PRNewswire/ RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Dose-dependent.
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented REGENXBIO Inc..
Digital, Informatics & Technology Solutions (DigITs)
As a firefighter and EMT in his New Jersey hometown, Paul Cortellesi doesn’t flinch when times get tough. So, when COVID-19 started to ramp up, he leapt into action and immediately volunteered to join the frontlines at MSK.
Mr. Cortellesi, a senior system architect in MSK’s DigITs group, was one of hundreds of clinical and nonclinical employees redeployed to assist with COVID-19-related operations. In March, he became a coordinator for MSK’s emergency response team to manage MSK’s supply of PPE. “There was no standard,” Mr. Cortellesi says. “We made it up as we went, based on best practices and the equipment we had.”
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy s 24th Annual Meeting
News provided by
Share this article
Share this article
ROCKVILLE, Md., April 27, 2021 /PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapy s 24
th Annual Meeting taking place from May 11 to 14, 2021, in virtual format. Presentations and posters will be available at https://www.asgct.org/.
Oral presentations include:
Abstract Title: Effects of Sexual Dimorphism and Genetic Background on AAV Tissue Transduction in Mice Following Intravenous Administration of a Diverse Capsid Pool (abstract #94)